October 08, 2009 06:00 ET

BIOLASE Wins Deloitte Tech Evolution Award

Special Award Category of the Technology Fast 500 Program

IRVINE, CA--(Marketwire - October 8, 2009) - BIOLASE Technology, Inc. (NASDAQ: BLTI) today announced that it is an inaugural winner of the Tech Evolution Award, an award that recognizes an elite group of companies that offer exceptional technologies that are transforming the technology industry. BIOLASE was announced as a recipient at a reception held on October 6 at The Island Hotel in Newport Beach, CA, by Deloitte & Touche LLP, host of the Tech Evolution Award and the Technology Fast 500.

According to Deloitte, the Tech Evolution Award recognizes companies whose proprietary technology contributes to their growth and success. Whether they are changing lives or enhancing productivity, these unique advances are helping the industry "soar to new heights" and make these companies the ones to watch.

David M. Mulder, BIOLASE Chief Executive Officer, said, "We are honored to have our market-leading laser technology recognized for this prestigious award. Our goal at BIOLASE has always been to develop laser systems and other technologies that provide clinically superior performance for many types of dentaland medical procedures, with less pain, faster recovery times and improved results over traditional instruments. This award is a tribute to all our employees."

About BIOLASE Technology, Inc.

BIOLASE Technology, Inc. (http://www.biolase.com), the world's leading dental laser company, develops, manufactures and markets Waterlase technology and lasers and related products that advance the practice of dentistry and medicine. The Company's products incorporate patented and patent pending technologies designed to provide clinically superior performance with reduced pain, faster and biological recovery times. BIOLASE's principal products are dental laser systems that perform a broad range of dental procedures, including cosmetic and complex surgical applications. Other products under development address ophthalmology, pain management and other medical and consumer markets.

This press release may contain forward-looking statements within the meaning of safe harbor provided by the Securities Reform Act of 1995 that are based on the current expectations and estimates by our management. These forward-looking statements can be identified through the use of words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," "may," "will," and variations of these words or similar expressions. Forward-looking statements are based on management's current, preliminary expectations and are subject to risks, uncertainties and other factors which may cause the Company's actual results to differ materially from the statements contained herein, and are described in the Company's reports it files with the Securities and Exchange Commission, including its annual and quarterly reports. No undue reliance should be placed on forward-looking statements. Such information is subject to change, and we undertake no obligation to update such statements.

Contact Information

  • For further information, please contact:
    Jill Bertotti
    Allen & Caron